Clinical Form 2 :CLINICAL MEDICATION WORKSHEET

Allergies: NKDA
Generic name Trade name Classification/Action (therapeutic effects for this patient)
Zidovudine AZT Antiviral; nucleoside reverse transcriptase inhibitor

Peak Onset Duration Dose (usual adult range)

0.5-1.5 h Unkown 4hr. 600 mg/day in divided doses 100x4, 200x3, 300x2

For IV meds (list incompatibilities with other Common side effects

meds/solutions) (>1%) Body as a whole: fever, dyspnea, malaise, weakness, myalgia,
Lansoprazole myopathy. CNS: headache, insomnia, dizziness, paresthesias, mild confusion,
anxiety, restlessness, agitation. GI: nausea, diarrhea, vomiting, anorexia, GI
pain. Hematologic: Bone marrow depression, granulocytopenia, and anemia.
Respiratory: Cough, wheezing. Skin: rash, itching, diaphoresis.

Medication alterations of lab values (ie-increased liver enzymes)

Watch CBC for decreased Granulocytes

Contraindications/warnings/Interactions (this patient)
Contraindications: Life threatening allergic reactions to any
of the components of the drug; lactic acidosis; pregnancy
(category C), lactation. Cautious use: impaired renal or
hepatic function, alcoholism; anemia; chemotherapy;
radiation therapy; bone marrow depression.
Interactions with other patient drugs or herbal medicines
Acetaminophen ganciclovir, interferon-alfa may enhance bone marrow
suppression; atovaquone, amphotericin B, asprin, dapsome,
doxorubicin, fluconazole, flycytosine, indomethacin, interferon alfa,
methadone, pentamidine, vincristine, valproic acid may increase risk
of AZT toxicity; probenecid will decrease AZT elimination, resulting in
increased serum levels and thus toxicity; Nelfinavir, rifampin, ritonavir
may decrease zidovudine (AZT) concentrations; other antiretroviral
agents may cause lactic acidosis and severe hapatomegaly with
steatosis; stavudine, doxorubicin may antagonize AZT effects.

Key nursing assessment/interventions/patient teaching before, during, and after administration medication
Evaluate Pt. at least weekly during the first month of therapy. Lab tests: baseline and frequent (at least every 2 weeks) blood counts,
CD4 (T4) lymphocyte count to detect hematologic toxicity. Myelosuppresion results in anemia, which commonly occurs after 4-6 wk
of therapy, and granulocytopenia in 6-8 wk. Frequently, both respond to dosage adjustment. Significant anemia (Hgb <7.5 g/dL or
reduction >25% of baseline value), or granulocyte count <750/mm3 (or reduction >50% of baseline) may require temporary
interruption of therapy and transfusions. Monitor for common adverse effects, especially severe headache, nausea, and myalgia. Pt.
and Family education: Contact physician proptly if health status worsens or any unusual symptoms develop. Understand that this
drug is not a cure for HIV infection; you will continue to be at risk for opportunistic infections. Do not share drugs with others; take
drug exactly as prescribed. Drug does not reduce the risk of transmission of HIV infection through out the body fluids